Human CCL22/MDC Alexa Fluor® 647-conjugated Antibody
R&D Systems, part of Bio-Techne | Catalog # IC3361R
Key Product Details
Species Reactivity
Applications
Label
Antibody Source
Product Specifications
Immunogen
Gly25-Gln93
Accession # O00626.1
Specificity
Clonality
Host
Isotype
Applications for Human CCL22/MDC Alexa Fluor® 647-conjugated Antibody
Intracellular Staining by Flow Cytometry
Sample: Human mature dendritic cells fixed with paraformaldehyde and permeabilized with saponin
Formulation, Preparation, and Storage
Purification
Formulation
Shipping
Stability & Storage
Background: CCL22/MDC
CCL22, also known as Stimulated T cell Chemotactic Protein (STCP-1), is a CC chemokine initially isolated from clones of monocyte-derived macrophages. Human CCL22 cDNA encodes a precursor protein of 93 amino acid residues with a 24 amino acid residue predicted signal peptide that is cleaved to yield a 69 amino acid residue mature 8 kDa protein. At the amino acid sequence level, CCL22 shows less than 35% identity to other CC chemokine family members. Human CCL22 is expressed in dendritic cells, macrophages and activated monocytes. In addition, CCL22 expression is also detected in the tissues of thymus, lymph node and appendix. The gene for human CCL22 has been mapped to chromosome 16 rather than chromosome 17 where the genes for many human CC chemokines are clustered. Recombinant or chemically synthesized mature CCL22 has been shown to induce chemotaxis or Ca2+ mobilization in dendritic cells, IL-2 activated NK cells, and activated T lymphocytes. A CD8+ T lymphocyte-derived secreted soluble activity that suppresses infection by primary non-syncytium-inducing and syncytium-inducing HIV-1 isolates and the T-cell line-adapted isolate HIV-1IIIB, has been identified as CCL22. Based on amino-terminal sequence analysis, the major CD8+ T lymphocyte-derived CCL22 protein yielded an amino-terminal sequence of YGANM, which is two amino acid residues shorter than the predicted mature CCL22. The difference in potency between the two mature CCL22 isoforms has not been determined.
References
- Godiska, R. et al. (1997) J. Exp. Med. 185:1595.
- Chang, M-S. et al. (1997) J. Biol. Chem. 272:25229.
- Pal, R. et al. (1997) Science 278:5338.
Alternate Names
Gene Symbol
UniProt
Additional CCL22/MDC Products
Product Documents for Human CCL22/MDC Alexa Fluor® 647-conjugated Antibody
Product Specific Notices for Human CCL22/MDC Alexa Fluor® 647-conjugated Antibody
This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.
For research use only